A 66-year-old man previously treated with eight prior line for follicular lymphoma received an anti-CD19 TRAC/PD-1 DKO CAR T cells that remained in CR on 12 months of follow-up without dose-limiting toxicity, GVHD, CRS, or neurotoxicity [246]. The gene discussed is CD19; the disease is follicular lymphoma.